Christo van Niekerk

1 ta ish

1. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

   Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt +16

   Maqola20152 iqtibos

   ABIABI:AkademIndex/2026.other.364686